RIYADH, Aug 19, 2024 - (ACN Newswire via SeaPRwire.com) - Saudi Arabia has navigated significant challenges in developing its data center infrastructure and 5G networks. Initially, the country faced hurdles such as high costs, regulatory barriers, and the need for substantial technological upgrades. However, through strategic investments and partnerships with global technology leaders, Saudi Arabia has steadily advanced its digital landscape.Initiatives like Vision 2030 have been pivotal, promoting digital transformation as a national priority. The government has implemented policies to foster innovation, streamline regulations, and attract foreign investments. Moreover, substantial funding in research and development, alongside the establishment of tech hubs and smart cities has accelerated progress. This resilience and forward-thinking approach have enabled Saudi Arabia to overcome early obstacles, positioning it as a burgeoning digital hub with a robust 5G and data center ecosystem, ready to support the nation's ambitious economic and technological goals.5G can transform Saudi Arabia into a Gigabit society, offering speeds up to 100 times faster than 4G and latency as low as 1ms. This technology enables telecom operators to ease network congestion in high-density areas, significantly enhancing the consumer experience while reducing the cost per bit. The result is a more efficient, reliable, and high-speed connectivity that supports the country's digital transformation and technological advancements.Overview of the event: The Data Center Xpo: where innovation meets strategy in the digital era. As data grows in importance, this summit is a beacon for professionals. Join visionaries and experts to explore trends, exchange viewpoints, and unveil transformative solutions. Beyond limits, it's a hub for networking, learning, and collaboration with insightful sessions, workshops, and discussions on data analytics, AI, and emerging tech.From demystifying the intricacies of data to deciphering the forthcoming wave of technological progress, the Data Centre Xpo seamlessly transforms knowledge into actionable insights. This conference is positioned to foster connections, forge partnerships, and unleash the limitless potential of excellence driven by the strategic application of data-driven solutions.Who will attend?Sultan Moraishedi, Group Chief Cybersecurity, Data And Business Excellence Officer,Red Sea Global.Abdullatif AlBlowi, Director Of Innovation And Technology Communications, Space & Technology Commission - CST.Anas Mosa,IT Director ,PIF Projects.Fahad Mahmoud Bedaiwi, Executive Vice President,Head Of Facilities, Management And Engineering,The Saudi National Bank.Mohammed Shah,IT & Smart City, Director Knowledge Economic City.Ahmed AlThuhaibi, Chief Of IT, Saudi Pro League.Kamal Farag, Digital Services Director,Human Resources Development Fund - HRDF - KSA.Mushtaq Ahmed, Enterprise Architecture And Digital Strategy Director, Saudi Post-SPL.Abdullah Abdulwasa, Chief Digital Officer, Al- Faisaliah Group.Sulafah Jabarti, Chair of the Digital Economy Committee, International Chamber of Commerce - Saudi Arabia.The event will cover topics like:Synergy Unveiled 5G Networks and Data centres Shaping Tomorrow's Digital Eco System.Unleashing the Potential of Al in Data Center Management.Efficient Remote Management Strategies for Modern Data Center.Unleashing the Power of Hyper Scalability Transforming the Data Center for Ultra Responsive Performance.Navigating the Hybrid Cloud Landscape.Towards Sustainable Computing Implementing Green Data Center Strategies.For more information and to register for Data Center Xpo click the link: https://exito-e.com/datacenterxpo/saudi/About ExitoExito, which means success in Spanish, embodies our commitment to the success of our customers. Each year, we host over 240 virtual and in-person conferences globally, bringing together audiences with world-class thought leaders and C-level executives across industries. Our meticulously crafted agendas, based on extensive research and valuable industry insights, facilitate business, knowledge transfer, deal flow, and impactful messaging for brands.For Media Enquiries, contact:Kasturi Nayak (Sr. Marketing Executive)Kasturi.nayak@exito-e.comEnquiry@exito-e.comExito Media Concepts Copyright 2024 ACN Newswire via SeaPRwire.com.

ISTANBUL, August 19, 2024 (ACN Newswire via SeaPRwire.com) - Türkiye received $4.7 billion in international direct investment in the first six months of this year. The Netherlands, the USA, Germany, Ireland, Norway, and the United Kingdom were the countries from which Türkiye received the most investment capital.BankPozitif's Chairman, Dr. Erkan KorkCommenting on the issue, BankPozitif Chairman Dr. Erkan Kork stated that despite the global decline in international direct investments, Türkiye has performed better, saying, "Our country is attracting significant investments from global actors with its entrepreneurial business culture, young population, and competitive products and services. Over the last 20 years, Türkiye has become a country that attracts 1% of the world's investments annually. The goal is to increase this rate to 1.5% by working even harder. Türkiye is not far from this target with the political stability provided by our President Recep Tayyip Erdogan, the reforms implemented, infrastructure investments, and investor-friendly policies. Under the vision and determined stance of our Minister of Treasury and Finance, Mr. Mehmet Simsek, our country is on the path to becoming a center for international investments.""It would be no surprise to hear news of new investments"Noting that Türkiye would achieve a much different picture with price stability, Kork said, "Türkiye Cumhuriyet Merkez Bankası Governor Fatih Karahan and his team are, so to speak, working tirelessly day and night. The improvement in the current account balance is evident. Recently, with the increase in our reserves and the correct steps taken, the Turkish Lira has reached an attractive position. Achieving price stability opens the door to the process leading to financial stability. In a country where there is financial stability, the appetite for investment is high," he said."Large-scale investments will come in the fintech sector"Dr. Erkan Kork stated that Türkiye would continue to attract qualified investments, especially those focused on the export of goods and services, saying, "The total value of international direct investment inflows to our country since 2002 has exceeded $268 billion. The investments received in the first six months of 2024 accounted for 28% of the current account deficit. This rate will increase further. Türkiye, which is a production, logistics, and management center for international investors, will continue to attract technology investments, particularly in fintech and e-commerce. I believe that capital inflows will continue not only from Europe and the USA but also from the Gulf countries," Dr. Kork said.About BankPozitifOperating in the field of digital banking, BankPozitif is a Turkey-based financial institution that enables individuals and businesses to carry out their financial transactions quickly and efficiently through a single digital platform. The bank offers digital investment banking with personalized financial solutions and innovative technologies for its customers. Source: BankPozitif [https://www.bankpozitif.com.tr]This press release is issued through EuropeNewswire.Net (www.europenewswire.net) and distributed by EmailWire (www.emailwire.com) – the gloabal newswire that provides Press Release Distribution with Guaranteed Results™. Copyright 2024 ACN Newswire via SeaPRwire.com.

Highlights:Strong analytical results from the inaugural drilling campaign for Q2 Metals including:CS-24-010: Cumulatively 181.1 metres ("m") at 1.67% Li2OWidest interval of 120.3 m at 1.72% Li2O including 19.0 m at 2.06% Li2OCS-24-007: Cumulatively 94.6 m at 1.52% Li2OWidest interval of 27.1 m at 1.96% Li2O including 11.1 m at 2.49% Li2OCS-24-008: Cumulatively 27.0 m at 1.63% Li2OWidest interval of 19.3m at 1.75% Li2O including 6.2 m at 2.23% Li2OCS-24-009: Cumulatively 115.9 m at 1.48% Li2OWidest interval of 82.1m at 1.43% Li2O including 15.7 ma t 1.88% Li2OVancouver, BC, Aug 19, 2024 - (ACN Newswire via SeaPRwire.com) - Q2 Metals Corp. (TSX.V:QTWO)(OTCQB:QUEXF)(FSE:458) ("Q2" or the "Company") is pleased to report on the first core assay results from drill holes CS-24-007 to CS-24-010 from the Spring 2024 Drill Campaign at the Cisco Lithium Property (the "Property" or the "Cisco Property") located within the greater Nemaska traditional territory of the Eeyou Istchee James Bay region of Quebec, Canada."These first four holes of our inaugural drill program at Cisco have exceeded our expectations with higher grades within some of the wider intervals such as Hole 10," said Q2 Metals VP of Exploration, Neil McCallum. "We look forward to releasing more analytical results in the coming weeks as they become available.""Between closing our financing earlier this month and the work we've done in the field, 2024 has been an exceptional year for Q2 Metals so far," said Q2 Metals President and CEO, Alicia Milne. "We have just begun our work at the Cisco Property, and having only completed 12 drill holes, these initial results are exceptionally promising."The analytical results reported herein represent the first 1,017 m of drilling over four (4) holes of the 3,753 m that were drilled over 12 holes at the Cisco Property. Initial visual results of those four holes were reported by the Company on June 17, 2024.The Spring 2024 Drill Campaign was designed to expand upon the 2023 drilling by the Property vendors. Hole CS-23-05 ("Hole 5") drilled by the Property vendor ended in pegmatite and assays results confirmed a total of 115.4 m at 1.40% Li2O, cumulatively within five (5) separate pegmatite intervals. Holes CS-24-009 and 010 ("Hole 10") were designed as 50 m westward step-outs from Hole 5. Assay results from these two holes confirmed wide intervals of spodumene pegmatite, with the widest interval reaching 120.3 m at 1.72% Li2O, including 19.0 m at 2.06% Li2O in Hole 10.Complete highlighted intervals from holes CS-24-007 to 010 are summarized in Table 1 and represented in Figure 1. All intervals of greater than two (2) metres of core-length are included in the table. Internal dilution of non-pegmatite material was limited to intervals of less than five (5) metres. No specific grade cap or lower cut-offs were used during grade and width calculations. All intervals are reported as core widths and mineralized intervals in all the holes drilled thus far are not representative of the true width as the modelled pegmatite zones are being refined with every additional hole.Figure 1. Map of Inaugural Drill Hole Analytical Results at Cisco PropertyTable 1. Summary of Analytical Results of Spring Drill Holes at Cisco PropertyResults from approximately 2,700 m of drilling eight (8) holes (CS-24-011 to CS-24-018) remain to be reported from the Spring 2024 Drill Campaign and will be released as soon as results are available. Drilling at the Cisco Property is ongoing and will continue into the fall of 2024.About the Cisco PropertyThe Cisco Property is comprised of 222 mineral claims and is 11,374 hectares in size. It is located less than 10 kilometres ("km") east of the Billy Diamond Highway, and is approximately 150 km north of Matagami, a small town that contains the closest rail link to much of James Bay. The Property lies within the greater Nemaska Community lands of the Eeyou Istchee Territory, James Bay, Quebec.The Property is situated along the Frotet Evans Greenstone Belt, comprised of a volcanic package dominated by mafic to felsic metavolcanic rocks, of the southern James Bay Lithium District, the same belt that hosts the Sirmac and Moblan lithium deposits, located 130 km and 180 km away, respectively.Sampling, Analytical Methods and QA/QC ProtocolsAll drill core samples were shipped to SGS Canada's preparation facility in Val D'Or, Quebec, for standard sample preparation (code PRP92) which includes drying at 105°C, crushing to 90% passing 2 mm, riffle split 500 g, and pulverize 85% passing 75 microns. The pulps are then shipped by air to SGS Canada's laboratory in Burnaby, BC, where the samples are homogenized and subsequently analyzed for multi-element (including Li and Ta) using sodium peroxide fusion with ICP-AES/MS finish (code GE_ICM91A50).A Quality Assurance / Quality Control protocol following industry best practices was incorporated into the sampling program.Qualified PersonNeil McCallum, B.Sc., P.Geol, is a registered permit holder with the Ordre des Géologues du Québec and Qualified Person as defined by National Instrument 43-101 - Standards of Disclosure for Mineral Projects, and has reviewed and approved the technical information in this news release. Mr. McCallum is a director and VP Exploration for Q2.About Q2 Metals CorpQ2 Metals is a Canadian mineral exploration company focused on unlocking its portfolio of lithium projects in the Eeyou Istchee James Bay region of Quebec, Canada, that includes both its 100-per-cent-owned Mia Lithium Property and the Cisco Lithium Property.The Cisco lithium property is located approximately 150 km north of Matagami, Que., and comprises 222 mineral claims and is 11,374 ha in size. The property has district-scale potential with an already identified mineralized zone and a discovery drill result of 115.4 metres at 1.40 percent lithium oxide (hole CS-23-05), cumulatively in five separate pegmatites.FOR FURTHER INFORMATION, PLEASE CONTACT:Alicia MilnePresident & CEOAlicia@Q2metals.comJason McBrideCorporate CommunicationsJason@Q2metals.comTelephone: 1 (800) 482-7560E-mail: info@Q2metals.comWWW.Q2Metals.comFollow the Company: Twitter, LinkedIn, Facebook, and InstagramForward-Looking StatementsThis news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian legislation. Forward-looking statements are typically identified by words such as: "believes", "expects", "anticipates", "intends", "estimates", "plans", "may", "should", "would", "will", "potential", "scheduled" or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved. Accordingly, all statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, any statements or plans regard the geological prospects of the Company's properties and the future exploration endeavors of the Company. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Forward-looking statements are based on a number of material factors and assumptions.Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those anticipated in such forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date specified in such statement. Forward looking statements in this news release include, but are not limited to, drilling results on the Cisco Property and inferences made therefrom, the potential scale of the Cisco Property, the focus of the Company's current and future exploration and drill programs, the scale, scope and location of future exploration and drilling activities, the Company's expectations in connection with the projects and exploration programs being met, the Company's objectives, goals or future plans, statements, exploration results, potential mineralization, the estimation of mineral resources, exploration and mine development plans, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from those in forward-looking statements include failure to obtain necessary approvals, variations in ore grade or recovery rates, changes in project parameters as plans continue to be refined, unsuccessful exploration results, changes in project parameters as plans continue to be refined, results of future resource estimates, future metal prices, availability of capital and financing on acceptable terms, general economic, market or business conditions, risks associated with regulatory changes, defects in title, availability of personnel, materials and equipment on a timely basis, accidents or equipment breakdowns, uninsured risks, delays in receiving government approvals, unanticipated environmental impacts on operations and costs to remedy same. Readers are cautioned that mineral exploration and development of mines is an inherently risky business and accordingly, the actual events may differ materially from those projected in the forward-looking statements. Additional risk factors are discussed in the section entitled "Risk Factors" in the Company's Management Discussion and Analysis for its recently completed fiscal period, which is available under Company's SEDAR profile at www.sedarplus.ca.Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.SOURCE: Q2 Metals Corp. Copyright 2024 ACN Newswire via SeaPRwire.com.

SINGAPORE, Aug 19, 2024 - (ACN Newswire via SeaPRwire.com) - The Perse School (Singapore) (TPSS) has won the tender conducted by the Economic Development Board (EDB) and Singapore Land Authority (SLA) in the first half of 2024 to provide foreign system education on the site at 58 Chestnut Drive.Under new leadership, led by CEO Johan Stromsater and school principal, Daniel Cross, TPSS targets a launch on the new campus in January 2025 with a future-focused Cambridge curriculum to equip students with academic, critical thinking, problem-solving, and leadership skills. TPSS is working towards ERF registration, and subject to regulatory approval, will open to students from 3-11 years of age from January 2025 and extend to include 12-18 years of age from 2026. This development marks the beginning of an exciting phase for TPSS as the new management seeks to offer a blend of British academic excellence, co-curricular opportunities, and pastoral care for students with fees starting at $22,750 per year."We are excited to bring The Perse's long-standing tradition of excellence to the International School sector in Singapore at a fee level that will make a top tier British education attainable," says Johan Stromsater, CEO of TPSS. “Our mission is to nurture happiness and success among our students, and we are committed to developing a diverse student community and an inspiring educational environment where every student can thrive."“Singapore’s diverse and high-quality selection of Foreign System Schools enhances our competitiveness as an attractive location for international companies and global talent. The Perse School (Singapore) will add to the landscape and serve the varied education needs of expatriate families here,” said Ms Ho Weng Si, Senior Vice President, Industry Manpower Development, EDB.The leadership team comprises:Johan Stromsater: CEO of Futuris Education and now CEO of TPSS, previously served as CEO of the Canadian International School in Singapore.Daniel Cross: Founding Principal of TPSS, is relocating to Singapore from Cambridge after 24 years at The Perse School Cambridge, most recently as Senior Deputy Head. "I am thrilled to bring the rich traditions and academic excellence of The Perse School to Singapore. We aim to provide a world-class education that blends academic rigour with a modern, future-focused skills curriculum."Kephren Sherry will be the Head of Pelicans (Early years) and Junior School, with 28 years in education and 12 years in the international school system. "Joining The Perse School Singapore is an incredible opportunity to shape the future of education for thousands of children."Innovative CurriculumTPSS will offer a comprehensive education from early years (3 years) to senior school (18 years). The school's curriculum will prepare students holistically for the challenges and opportunities of the future, equipping students with academic rigour, critical thinking, problem-solving, and leadership skills. The Pelican Junior and Senior programs will follow the International Cambridge curriculum until iGCSE, with Years 12 and 13 adopting the International Baccalaureate (IB). The curriculum will have a strong emphasis on STEM subjects and bilingual programs, and will also integrate skills such as robotics, coding, and entrepreneurship into the core timetable.State-of-the-Art FacilitiesThe new campus will be located at 58 Chestnut Drive, the former site of Chestnut Drive Secondary School. The campus is undergoing significant renovations to create a state-of-the-art learning environment, with facilities that will include modern classrooms, a multi-purpose sports field, and specialised arts, music, and drama learning spaces. The first phase of the development is expected to be completed in time for the school opening in January 2025, with further development phases planned outside of school term time throughout 2025.Mission and Values of The Perse School SingaporeTPSS is under licence from The Perse School Cambridge International who will closely support the schools design and setup. With over 400 years of British academic excellence and heritage, the setup will be guided by a commitment towards academic excellence, extracurricular activity, and pastoral care to nurture well-rounded students. This is underpinned by The Perse core values of Endeavour, Intellectual Curiosity, Breadth and Balance, and Care for One Another and the Environment.Ed Elliott, Head of The Perse School Cambridge, remarks: "The close collaboration between our campuses will ensure the consistent delivery of The Perse's high standards and values. In a typical year, 40-50 Perse Cambridge pupils will receive offers from Oxford or Cambridge Universities. Perse Cambridge students received a combined 718 university offers this year, including 589 from the UK's prestigious Russell Group universities. Our success in university placements stems from an excellent academic education, complemented by our commitment to individual personal development through extracurricular programs like our Perse Exploration Society. These initiatives prepare students for further education, employment and adult life. Offering pathways to higher education and careers has been a hallmark of The Perse for centuries, and we aspire to extend these opportunities to our students in Singapore."A bank of imagery available for media use, including the leadership team, can be found on this drive link.About The Perse School (Singapore)The Perse School (Singapore), owned and operated by Future Education PTE LTD, offers an outstanding education affiliated with The Perse School Cambridge International. Perse Singapore's focus is on academic excellence, extracurricular activity, and pastoral care to nurture rounded students. Our core values—Endeavour, Intellectual Curiosity, Breadth and Balance, and One Another and the Environment—guide and shape the school's culture.About The Perse School CambridgeThe Perse School offers an excellent academic education complemented by extracurricular programs like the Perse Exploration Society. For more details, visit www.perse.co.uk.Contact: knsawtell@perse.co.uk or sdarmitage@perse.co.ukContact Information:For media enquiries or more information, please email Contact@perse.com.sg. Social Media Links:Facebook Instagram: @Theperseschoolsingapore LinkedIn http://www.Perse.com.sgFor more information, please visit www.perse.com.sg Copyright 2024 ACN Newswire via SeaPRwire.com.

SINGAPORE, Aug 19, 2024 - (ACN Newswire via SeaPRwire.com) - A clear testament to the success of its past editions, Rockbird Media is thrilled to announce the 12th Retail & E-Commerce Summit Asia, set to unfold on September 26, 2024, at the One Farrer Hotel in Singapore. Themed “Retail Revolution: The Limitless Growth in the Age of AI,” this premier event is poised to dive deep into the seismic shifts reshaping the retail and e-commerce landscape.Despite its smaller population compared to regional neighbors, Singapore is on track to achieve a remarkable US$5,901 million in retail and e-commerce revenue by 2024. This impressive growth highlights the city-state's burgeoning role in the global digital economy and underscores the urgent need for businesses to adapt and thrive in this dynamic environment.The summit will offer an unparalleled opportunity for industry professionals to explore the latest trends and technologies driving the retail revolution. Attendees will benefit from keynote presentations, interactive breakout sessions, and panel discussions featuring leading experts. Personalized agendas, 1-on-1 meetings, and vibrant networking sessions will also be integral to the event, ensuring that each participant gains actionable insights and valuable connections.Singapore stands at the forefront of e-commerce innovation, and this summit will provide crucial insights into harnessing AI and technology for limitless growth, bringing together 100+ industry leaders and experts to shape the future of retail.For more information, including registration details, the in-depth agenda, speaker updates, pricing, and more, please visit https://rockbirdmedia.com/all_b2b/resa-singapore-2024/.About rockbird mediaRockbird media is an international business media company that produces B2B events and offers business solutions.Whether it is through online media and content, must-have business intelligence and analytics, effective networking, and partnering solutions, we help businesses and professionals learn more about the latest trends, and know more about their customers, peers, and competition, to make that decision that allows them to grow.Media contact:annjubelle@rockbirdmedia.com Copyright 2024 ACN Newswire via SeaPRwire.com.

KUALA LUMPUR, Aug 19, 2024 - (ACN Newswire via SeaPRwire.com) - With rapid HR advancements on the horizon, Rockbird Media is just in time to announce the 16th edition of the HR Leaders & HR Tech Strategy Meeting, taking place on September 24, 2024, at Berjaya Times Square, Kuala Lumpur, Malaysia. The event, themed “Advancing into the Nexus of Human and Technology,” will be a crucial platform for addressing the evolving role of technology in HR.As Malaysia’s HR Technology market is poised for a significant 12% compound annual growth rate (CAGR) over the next five years, this year’s gathering will focus on equipping HR professionals with strategies to integrate cutting-edge tools and bridge the technological skill gap. Attendees will explore methods to enhance operational efficiency, boost employee engagement, and optimize legacy systems with modern technology.One in a series of successful HR Strategy Meetings across Southeast Asia, its 16th edition will emphasize the urgent need for HR leaders to strategically adapt to technological advancements, providing a unique opportunity to engage with industry experts, share best practices, and prepare for the future.The event will feature keynote addresses, interactive breakout sessions, panel discussions, and one-on-one meetings, designed to offer actionable insights and foster networking among over 100+ CHROs and HR leaders from various industries.For more information, including registration details, the in-depth agenda, speaker updates, pricing, and more, please visit: https://rockbirdmedia.com/all_b2b/hrmy2024/About rockbird mediaRockbird media is an international business media company that produces B2B events and offers business solutions.Whether it is through online media and content, must-have business intelligence and analytics, effective networking, and partnering solutions, we help businesses and professionals learn more about the latest trends, and know more about their customers, peers, and competition, to make that decision that allows them to grow.Media contact:annjubelle@rockbirdmedia.com Copyright 2024 ACN Newswire via SeaPRwire.com.

Results Highlights:- Revenue and net profit reached US$78.9 million and US$18.8 million, respectively.- APAC market revenue grew significantly by 31.0%, driven by both organic growth and contributions from SJ Medicare and PT Revass, the South Korean and Indonesian distributors acquired in Q4 2023.- Total sales volume of proprietary products remained at 717,000 units.- In 1H2024, the Group made extensive efforts to integrate eucatech AG, a German company acquired last year, into its operations and reorganize its production lines, and expects eucatech AG to resume production and shipment in Q3.- The Group has been actively registering products of eucatech AG in various countries and regions, and eucaLimus, a coronary drug eluting stent, has already received registration approval in Malaysia.- For the clinical studies of TricValve, patient enrollment has commenced in 13 hospitals in the PRC. In Japan, the Group is working closely with the Pharmaceuticals and Medical Devices Agency (“PMDA”) and the US Food and Drug Administration (“FDA”) to prepare for the clinical trial and registration process.- In May 2024, the Group engaged the main contractor for its largest R&D and manufacturing facility in Hangzhou, which is expected to begin operation in 2027, adding an annual production capacity of 2.4 million product units upon commencement of production.- The Group’s financial position remained strong, as evidenced by the cash and bank balances of US$246.7 million as of June 30, 2024.- The Group expects to maintain a stable dividend policy, demonstrating its confidence in future prospects.HONG KONG, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”) procedures, today announced its interim results for the six months ended June 30, 2024 (the “Reporting Period”), with revenue and profit for the period attributable to owners of the Company maintained at US$78.9 million and US$18.8 million respectively despite various market challenges.Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “The global economy has been highly volatile in recent years, as a result of factors such as geopolitical tensions and major central banks shifting their monetary policies. Albeit the challenging external environment, we were able to seize the opportunity to implement a series of measures to enhance operational efficiency and integrate the businesses of SJ Medicare, PT Revass and eucatech AG acquired last year into our Group. We believe the investments made in the first half year are crucial to supporting our future sustainable growth.”For the Reporting Period, the Group’s revenue decreased slightly by 3.1% to US$78.9 million, mainly attributable to decline in sales volume in the US due to integration of Cardiovascular Systems, Inc. (“CSI”) into Abbott Laboratories (“Abbott”), and in the PRC market due to on-going impact of anti-corruption campaign, as well as the Group’s termination of distribution of certain third-party products, despite the significant sales growth recorded in APAC, as well as the modest revenue growth in Japan in terms of Japanese Yen. Excluding the impact of the foreign exchange fluctuations, total revenue would have recorded a slight year-on-year increase of 0.6%. Gross profit amounted to US$55.8 million while gross profit margin stood at 70.7%.Despite the decline in revenue and the short-term increase in expenses incurred by the Group’s series of measures to enhance operational efficiency and integrate the businesses acquired in the previous year, the Group maintained a healthy level of net profit for the first half of 2024. It is worth noting that, excluding the operating expenses of the newly acquired businesses, the three core operating expenses, namely selling and distribution expenses, general and administrative expenses and research and development expenses, for the first half of 2024, remained flat against the same period last year. As of June 30, 2024, the Group maintained a strong financial position with cash and bank balances of approximately US$246.7 million, laying a solid foundation to support its growth objective.Robust Balloon Sales in APAC and EMEAThe Group’s proprietary balloon products continued to gain traction worldwide. In the first half of 2024, revenue from the APAC market saw organic growth of a marked 8.6% year-on-year, thanks to strong balloon sales growth in markets such as Malaysia, Hong Kong, India, Vietnam and Singapore. Particularly, the latest generation of scoring balloon, Scoreflex TRIO, recorded a rapid rise in sales since it was launched in Malaysia in early 2024. Together with the additional contribution of US$4.3 million from the SJ Medicare and PT Revass, distributors acquired in South Korea and Indonesia respectively in Q4 2023, the revenue generated from APAC amounted to a total of US$24.0 million, representing a significant increase of 31.0% year-on-year.In addition, mainly attributable to the increase in sales of the Group’s proprietary balloon products in direct sales markets such as Germany, France and Spain, as well as distributor sales markets including Czech Republic and Slovakia, revenue generated from EMEA slightly increased by 1.3% to US$19.2 million, even being partly offset by the termination of distribution agreement with CSI for atherectomy products.During the first half of 2024, Scoreflex TRIO continued to drive revenue generated from Japan, the Group’s largest single-country market, in terms of Japanese Yen, achieving an 8.1% increase year-on-year.Integrating Newly Acquired Business to Drive Future GrowthFollowing the acquisition of eucatech AG in November 2023, extensive efforts were made to integrate eucatech AG into the Group’s operation and reorganize production lines. The Group has been actively registering eucatech AG’s four products, namely eucaLimus, Support C, Resistant, and VITUS, in various countries and regions to avail those products via the Group’s own sales network to physicians and patients in different markets. In the first half of 2024, eucaLimus was granted registration approval in Malaysia, one of the Group’s direct sales markets. Registration applications for eucatech AG’s products have also been submitted to relevant regulatory bodies in Hong Kong, Malaysia, Switzerland, Italy and Saudi Arabia and are pending approval. The Group also promoted eucatech AG’s products at major conferences including EuroPCR, as well as educated distributors about these offerings so that sales could be ramped up smoothly once the products become available.In April 2024, the Group supported eucatech AG’s on-site Medical Device Directive (“MDD”) and Medical Device Regulation (“MDR”) surveillance audit, as such, was able to extend the CE Mark expiration dates for their 4 products under the MDD framework. All these efforts are expected to see eucatech AG resume production and shipment in the third quarter of the year.Relentless Drive to Translate Innovations into Thriving Product LinesAs of June 30, 2024, OrbusNeich had an aggregate of over 50 approved products. The Group has maintained a steadfast commitment to translating its R&D efforts into commercially successful products. To date, the Group achieved major milestones, including:- Obtaining NMPA approval for Teleport Neuro, FDA approval for Teleport XT and JADE PLUS 14/18/35 OTW, CE Mark for Sapphire ULTRA and Sapphire NC ULTRA;- Submission of registration applications to the NMPA for its Guiding Catheter;- Completion of the clinical trial patient enrollment for Scoreflex TRIO in the PRC, with the NMPA application expected to be submitted in Q3 2024;- Preparation for the Sapphire 3 clinical trial in the US, with enrollment scheduled to begin in Q3 2024.Alongside these regulatory and commercialization efforts, the Group continued to invest in new pipeline products, such as the Corepass modular microcatheter, support catheter and the JADE Plus. Registration applications for these innovative offerings are planned for submission to various authorities in 2024.Meanwhile, the joint venture OrbusNeich P&F made significant efforts to advance the clinical studies of TricValve in two major Asia Pacific markets. Patient enrollment has commenced in the PRC for its clinical trial, and the clinical trial and registration process in Japan is being prepared in close collaboration with the PMDA and the FDA.Boosting Production Capacity through Rigorous Quality Processes and Operational ExcellenceThe Group has always prioritized product quality, which is ensured by a robust quality management system. During the Reporting Period, various sites successfully passed audits conducted by various regulatory and notifying bodies. Furthermore, the Group remains committed to enhancing operational efficiency and reducing production costs by continually optimizing manufacturing processes, work-in-progress inventory levels, and employee productivity. To meet future production needs, the Group will construct its largest R&D and manufacturing facility in Hangzhou, the PRC, for which it engaged the main contractor in May 2024 and which is expected to begin operation in 2027, adding an annual production capacity of 2.4 million units of products upon commencement of production.Mr. Chien concluded: “Looking ahead, as new sales strategies are being executed in the PRC and the US markets, we expect these key geographies will regain growth momentum in second half of the year. Meanwhile, OrbusNeich has maintained active efforts to expand our market presence. On the product front, we are leveraging our comprehensive sales network and brand recognition to market innovative endovascular intervention products to enhance the solutions we provide to the physicians. New products from eucatech AG which is expected to resume production soon will also contribute to improved profitability. We are also actively identifying M&A opportunities that align with our strategic priorities and position us for sustainable growth. Despite the first-half headwinds, we remain optimistic about restoring growth momentum soon and expect to maintain a stable dividend policy for shareholders based on our robust financial position.”- End -About OrbusNeich Medical Group Holdings LimitedOrbusNeich is a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, OrbusNeich sells its products in more than 70 countries and regions worldwide. It is also actively expanding into neuro vascular intervention and structural heart disease. As of June 30, 2024, OrbusNeich has more than 230 granted patents and published patent applications worldwide. Its in-house R&D team has more than two decades of product development experience and has developed world-leading proprietary technologies.For more information, please visit the Group’s official website: https://orbusneich.com/. Copyright 2024 ACN Newswire via SeaPRwire.com.

BRISBANE, AUS, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - CISO FSI ANZ 2024 invites cybersecurity professionals in the Financial Services Industry to join this free virtual event designed to inspire and share intelligence. The online gathering will cover everything from cyber strategy, risk management, governance, program and incident management, leadership, to enabling business growth.CISO FSI ANZ offers a unique opportunity to expand your knowledge and find ways to avoid cyber threats in the FSI industry. Benchmark your strategies with peers and learn how to get buy-in and collaboration in your projects across the board.Key topics include:Strategies to advance your company’s cyber security maturity modelsHow to align cyber risk management with the company's goalsComplying with APRA regulations in Australia and MBIE in New ZealandThe impacts of the privacy act reform in information securitySuccessful practices to mitigate the increase of third-party risksBridging the talent gap by investing in culture, education and trainingNavigating the “AI high” by leveraging its benefits while minimising its risksCISO FSI ANZ is an essential online event for those looking to advance their knowledge and network within the cybersecurity community. Join us on 12 September 2024 at 10 AM AEDT or 12 PM NZT.It’s free! Register now: https://bit.ly/4dpyOUYVisit website: https://ciso-fsi-anz.coriniumintelligence.com/About Corinium IntelligenceCorinium Intelligence is a global leader in providing conferences, events, and content to the information and technology industries. With a focus on fostering collaboration and innovation, Corinium Intelligence brings together industry leaders to share insights, best practices, and strategies for success.Media Contact:Claudia Peixoto, Marketing Managerclaudia.peixoto@coriniumgroup.com Copyright 2024 ACN Newswire via SeaPRwire.com.

CANBERA, AUSTRALIA, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - CISO Canberra invites cyber security professionals to explore the critical role of public sector cyber security in protecting the public and driving transformative leadership strategies for delivering the 2023-2030 Australian Cyber Security Strategy.The tech demo exhibition will showcase cutting-edge services and innovations driving change in the cybersecurity landscape. InfoSec leaders will share their strategic insights in no-nonsense talks, providing valuable substance over empty rhetoric.Key themes include:STRENGTH IN UNITY: Building robust shields against cyber threats by navigating the 2023-2030 Australian Cyber Security Strategy to be the most secured nation.AWARENESS, EMPOWERMENT, & COORDINATION: Maturing cyber security culture through collective responsibility and collaborative efforts for enhanced resilience.PROACTIVE GRC MANAGEMENT: Integrating Zero Trust and evaluating risks in supply chains, data and AI to empower decision making at the pace of innovation.MODERNISING THREAT DETECTION & RESPONSE: Embracing cutting-edge technologies and strategies to advance security, integrity and resilience capabilities.CISO Canberra 2024 is an essential event for those looking to advance their knowledge and network within the cybersecurity community. Join us at the Canberra Rex Hotel on 14 November 2024 for an event that promises to inspire and empower.Use the code ACNNEWS20 for 20% off the ticket price.Register here: https://bit.ly/4dqzPfbVisit website: https://ciso-bris.coriniumintelligence.com/ About Corinium IntelligenceCorinium Intelligence is a global leader in providing conferences, events, and content to the information and technology industries. With a focus on fostering collaboration and innovation, Corinium Intelligence brings together industry leaders to share insights, best practices, and strategies for success.Media Contact:Claudia Peixoto, Marketing Managerclaudia.peixoto@coriniumgroup.com Copyright 2024 ACN Newswire via SeaPRwire.com.

SHENZHEN, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - On August 15, 2024, China Medical System Holdings Limited (“CMS” or the “Company”) released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023. In the case that all medicines were directly sold by the Company, the turnover was RMB4,287.5 million, representing a decrease of 22.6% compared with 1H 2023, an increase of 8.9% compared with 2H 2023; Among which, the total revenue of non-National VBP exclusive products and innovative products was RMB2,404.7 million, accounting for 56.1% of CMS’s revenue in the case that all medicines were directly sold by the Company. Profit for the period was RMB903.4 million, representing a decrease of 52.8% compared with 1H 2023, a substantial increase of 92.8% compared with 2H 2023.The year 2024, not only marks the first year of the commercialization of CMS’s innovative products, but also a crucial point for the release of National Volume Based Procurement (“National VBP”) impact on its financial performance. Deanxit entered the seventh batch of National VBP in November 2022, Plendil and Ursofalk entered the eighth batch of National VBP in July 2023, and none of the three original drugs were selected, which had a negative impact on the Company’s business performance. In 1H 2024, the Company’s overall performance showed a growth trend compared with 2H 2023, indicating that CMS has basically digested the impact of National VBP and successfully entered the "New Product Era" where non-national VBP exclusive products and innovative products drive its growth.With the approval for marketing of LUMEBLUE (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) in June and METOJECT (Methotrexate Injection)’s additional indication of active rheumatoid arthritis (RA) in adults in July this year, CMS's innovative drug portfolio in the commercialization stage has expanded into 5 products (including 6 indications); simultaneously with a rich and differentiated innovative pipeline reserve. Gathering the power of innovation and riding the momentum of development, CMS is comprehensively shaping new drivers for development with a healthier product structure, further opening up a new cycle of quality development.The "Collaborative and In-house" dual-engine R&D model drives the simultaneous improvement in quantity and quality of the pipeline, accelerating the transformation of innovative biotechnologyA profound innovative drug R&D pipeline is an important driving force for the long-term development of CMS. The Company adheres to the purpose of innovation for meeting the unmet clinical needs and solving the difficulties of patient medication, and promotes innovation development through a two-wheel drive of “Collaborative R&D and In-house R&D”, continuously deploying FIC (first-in-class) and BIC (best-in-class) innovative products, and enhancing the capabilities and efficiency of research and clinical development to achieve a rapid transformation of scientific outcomes into social and commercial values.As of now, CMS's innovative product portfolio approved for marketing in China has been expanded into 5 products (including 6 indications), among which, 4 innovative drugs (VALTOCO, ILUMETRI, METOJECT - psoriasis indication, VELPHORO) have been included in the National Reimbursement Drug List (NRDL) and entered large-scale clinical application; also, CMS newly added LUMEBLUE and METOJECT (RA), for being approved for marketing in China recently.CMS has also steadily advanced the clinical development of innovative products. Currently, Desidustat Tablets is under NDA review in China; Also, a total of about 10 projects have been prepared/launched for their registrational clinical trials, mainly randomized controlled trials (RCT).At the same time, the Company had continued to strengthen basic research and independent innovation capabilities, and successfully promoted more than 10 in-house R&D projects, among which, three innovative drugs (VEGFA/ANG2 Tetravalent Bispecific Antibody, Highly Selective TYK2 Inhibitor CMS-D001 Tablets, and GnRH Receptor Antagonist CMS-D002 Capsules) have entered the clinical development stage.In addition, the Company’s innovative pipeline has continued to expand. CMS Skinhealth collaborated with Incyte once again, and has obtained exclusive license to research, develop, register and commercialize povorcitinib, a selective oral small-molecule JAK1 inhibitor, in countries/territories including Mainland China, Hong Kong, Macau, Taiwan Region and 11 Southeast Asian countries. This further enriched the product portfolio of CMS Skinhealth in the treatment of vitiligo and other immune-mediated dermatology diseases.Subsequently, CMS will continue to produce innovative products with higher efficiency and more controllable costs every year, accelerating the release of innovative value and embracing quality and sustainable performance growth through a healthy product structure dominated by non-National VBP exclusive products and innovative products.Successful commercialization system releases the clinical value of innovative products in an efficient and collaborative mannerAfter 32 years of deep cultivation in specialty therapeutical fields, successful commercialization capability is one of CMS’s core competitiveness. By continuously reinforcing and integrating its commercialization platform, it has achieved in-depth development of its three major business segments including cardio-cerebrovascular/gastroenterology, dermatology, and ophthalmology, and expanded its boundaries in related fields. Additionally, the Company established a highly qualified, professional promotion team with strong execution, as well as extensive channel and resource coverage, which has laid a solid foundation for the rapid market entry and brand building of its innovative products.Four innovative drugs of CMS have entered large-scale clinical applications, covering various disease fields such as central nervous system, dermatology, nephrology, and gastroenterology, and developed synergistically with the existing marketed products in promotion team and channels. Meanwhile, leveraging on the opportunity of being included in the NRDL, CMS is advancing hospital development, brand building, real world studies and medically-driven academic promotion. CMS is improving patients’ accessibility to innovative drugs with the help of patient aid and disease knowledge popularization programs, promoting the release of products’ clinical value.The Dermatology and Medical Aesthetic Business "CMS Skinhealth" regards dermatology prescription products as its core, and extends to light medical aesthetic products and dermatology-grade skincare products, continuously improving the construction of a full life-cycle skin-health management platform covering dermatological treatment, skincare, and medical aesthetics through internal development and external collaboration. In terms of clinical development of dermatology prescription drugs, CMS has completed the Pivotal Real World Study for ruxolibinib cream in vitiligo, and is advancing the registration application process in Mainland China. At the same time, it has continuously complemented the regenerative light medical aesthetic portfolio, among which the China’s medical device registration application of the Poly-L-lactic Acid Microparticle Filler Injection has been accepted by the NMPA during the Reporting Period; and the Company has newly obtained exclusive licenses of three regenerative light medical aesthetic products (Polycaprolactone Microsphere Gel for Injection, Calcium Hydroxylapatite Microsphere Gel for Injection, and Decellularized Extracellular Matrix Implant), which are currently under the registrational clinical trial stage in China.The results announcement shows that, as of the end of June, the promotion network of CMS has covered over 55,000 hospitals and medical institutions, and approximately 280 thousand retail pharmacies in China.Leveraging the accumulated advantages in cardio-cerebrovascular, gastroenterology, central nervous system, nephrology, ophthalmology, dermatology and other specialty therapeutical fields, CMS steadily releases the scale effect of its specialty businesses, and builds high competition barriers, creating broad commercial potential for its innovative products and exclusive products.Drawing up the internationalization layout to gather momentum for the incremental marketIntegrating the advantageous resources of the Company, its Southeast Asia business “Rxilient Health”, shares and expands the successful experience of CMS gained from the China market, as well as global quality products and innovative technological resources, into the Southeast Asia market. This accelerates the improvement of the platform integrating “R&D, manufacture, and commercialization” of the Southeast Asia business, empowering Chinese and global pharmaceutical companies to implement the “overseas development” strategy, and also opening up a larger space for incremental development opportunities for CMS.As of the end of June, Rxilient Health has established a competitive product portfolio with more than ten differentiated products, covering therapeutic areas such as oncology, central nervous system, autoimmune, dermatology, and ophthalmology, etc. Rxilient Health is accelerating the relevant work on the market registration processes in Southeast Asian countries for innovative pipeline products, such as ruxolitinib cream, Methylthioninium Chloride Enteric-coated Sustained-release Tablets, and Diazepam Nasal Spray, etc. Furthermore, Rxilient Health collaborated with Junshi Biosciences to promote the registration process of toripalimab (anti-PD-1 monoclonal antibody) in multiple countries in Southeast Asia, aiming to benefit local cancer patients as soon as possible.In December last year, the Company and Rxilient Health joined hands with Pharmaron and other partners to complete the purchase of the Singapore manufacturing plant. This year, all relevant parties have been orderly advancing a series of work for the Singapore manufacturing plant, including equipment testing, quality verification, and production quality system certification, etc., so as to accelerate the CDMO business development, and to optimize the Company’s overseas supply chain and manufacturing capabilities. The business layout will further facilitate more inter-industry cooperation between CMS and global partners in the future, thus jointly building a win-win medical innovation ecosystem with mutual benefits.ConclusionSince its establishment in 1992, CMS has followed the development pattern of the industry and has promoted three significant strategic transformations successfully with a forward-looking vision. The Company started as an agent of imported original drugs, gradually developed to control the rights of original/exclusive products, and then achieved a comprehensive innovative transformation. Each step of the transformation is in sync with the industry development trends. CMS steadily aims towards the ultimate goal, and constantly builds up its strength and resilience to persist through the industry development cycle. With the gradual release of the impact of national VBP on its financial performance, CMS has been transforming into a brand-new company. While embracing the innovation achievements in each stage, CMS is fully prepared for a sustainable and healthier development in the future.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a "bridgehead" for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactChina Medical System Holdings Ltd.CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2024 ACN Newswire via SeaPRwire.com.